Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib for achieving deep molecular response toward treatment-free remission in CML
2018-004564-59Phase 2Active
- Sponsor
- Heidelberg University
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in chronic myelogenous leukemia (CML), sponsored by Heidelberg University. Primary endpoint: Ponatinib treatment duration. Started May 2019; status: active.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2018-004564-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004564-59.